A5029813708- Diabetes Treatment and Management
- Metabolism, Diabetes, and Cancer
- Diabetes Management and Research
- Gastric Cancer Management and Outcomes
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Lipoproteins and Cardiovascular Health
- Botulinum Toxin and Related Neurological Disorders
- Pain Mechanisms and Treatments
- Liver Disease Diagnosis and Treatment
- Diet and metabolism studies
- Medication Adherence and Compliance
- Physical Activity and Health
- Renal function and acid-base balance
- Cardiovascular and exercise physiology
- Diabetes and associated disorders
- Regulation of Appetite and Obesity
- Pancreatic function and diabetes
- Acupuncture Treatment Research Studies
- Pharmacology and Obesity Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Management and Education
- High Altitude and Hypoxia
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Chronic Disease Management Strategies
Novo Nordisk (Denmark)
2023-2024
Steno Diabetes Centers
2017-2023
Danish Diabetes Association
2023
Gentofte Hospital
2019-2021
Copenhagen University Hospital
2021
Aarhus University
2017-2019
Capital Region of Denmark
2017
Real-world data provide insight into how medications perform in clinical practice. The PIONEER REAL Switzerland study aimed to understand outcomes with oral semaglutide adults type 2 diabetes (T2D). was a 34–44-week, multicentre, prospective, non-interventional, single-arm of T2D naïve injectable glucose-lowering medication who were initiated on routine primary endpoint change glycated haemoglobin (HbA1c) from baseline (BL) end (EOS); secondary endpoints included body weight (BW) BL EOS and...
Abstract Aim PIONEER REAL Canada examined real‐world clinical outcomes associated with the use of once‐daily oral semaglutide in adults type 2 diabetes. Materials and Methods This was a 34‐ to 44‐week, multicentre, prospective, open‐label, non‐interventional study who were treatment‐naive injectable glucose‐lowering medication initiated routine practice. The primary endpoint change glycated haemoglobin (HbA1c) from baseline end (EoS). Secondary endpoints assessed at EoS body weight (BW);...
In this phase 4, multicentre, prospective, non-interventional PIONEER REAL Netherlands study, we assessed clinical outcomes associated with once-daily oral semaglutide use in real-world practice adults living type 2 diabetes (T2D) naïve to injectable glucose-lowering medication. Participants initiated on were followed for 34–44 weeks. Change glycated haemoglobin (HbA1c) from baseline (BL) end of study (EOS) was the primary endpoint; secondary endpoints included change body weight (BW) BL...
The study was designed to assess outcomes with once-daily oral semaglutide in adults type 2 diabetes (T2D) naïve injectable glucose-lowering agents, Swedish clinical practice.
PIONEER REAL Japan was a non-interventional prospective study of oral semaglutide in adults with type 2 diabetes Japanese clinical practice.
ABSTRACT Aims/Introduction PIONEER REAL Japan was a non‐interventional, multicenter, prospective study investigating oral semaglutide in adults with type 2 diabetes routine clinical practice. We report baseline characteristics of participants enrolled this study. Materials and Methods Adults aged ≥20 years but no previous treatment injectable glucose‐lowering medication were enrolled. Participants initiated at their treating physician's discretion followed for 34–44 weeks. stratified into...
Oral semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA) approved for improving glycemic control in adults with type 2 diabetes (T2D). The PIONEER REAL program evaluates clinical and patient-reported outcomes of oral treatment as part routine practice across 13 countries. Here, data from Canada, Denmark, Italy, the Netherlands, Sweden, Switzerland, UK are pooled analyzed to address satisfaction well glycated hemoglobin (HbA
To examine whether fasting plasma liver-expressed antimicrobial peptide 2 (FP-LEAP2) is associated with markers of cardiometabolic disease susceptibility in a cohort prediabetes and overweight/obesity antidiabetic interventions affect FP-LEAP2 levels. The analysis included 115 individuals [hemoglobin A1c (HbA1c) 39-47 mmol/mol, 5.7%-6.4%] [body mass index (BMI) ≥ 25 kg/m2] from randomized controlled trial. Changes levels were assessed relation to treatment dapagliflozin (10 mg once daily),...
It is not known if incidence rates for diabetic distal symmetric polyneuropathy (DSPN) are decreasing, as they other complications. Here, we investigated of DSPN in type 1 and 2 diabetes a large population-based study.
To assess the level of adherence to glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment using real-world data and investigate sociodemographic clinical factors associated with discontinuation GLP-1RAs.
Introduction The primary aim of this study is to compare the efficacy three short-term glucose-lowering interventions (exercise, metformin and dapagliflozin) on glycaemic variability in overweight or obese men women with elevated diabetes risk (ie, prediabetes, defined as haemoglobin A 1c (HbA )39–47 mmol/mol / 5.7%–6.4%). secondary aims are investigate effects body composition cardiometabolic factors. Methods analysis Pre-D Trial an investigator-initiated, randomised, controlled, parallel,...
Ambiguity exists in relation to the role of physical activity (PA) for cardiovascular disease (CVD) risk reduction. We examined interplay between PA dimensions and more conventional CVD factors assess which were associated with first event whether subgroup differences exist. A total 1449 individuals [median age 65.8 (IQR: 61.2, 70.7) years] low high type 2 diabetes free from Danish ADDITION-PRO study included survival analysis. was measured by individually calibrated heart rate movement...
Knowledge on how energy intake and macronutrients are distributed during the day role of daily eating patterns in body composition among adults with overweight/obesity prediabetes is lacking. Therefore, we evaluated diurnal dietary studied associations fat percentage. A total 119 were included (mean (SD) HbA1c 41 (2.3) mmol/mol, BMI 31.5 (5.0) kg/m2, age 57.8 (9.3) years, 44% men). Information was obtained from self-reported food records for three consecutive days. All foods beverages...
OBJECTIVE Diabetic ketoacidosis (DKA) is a life-threatening but preventable complication in people with type 1 diabetes. We aimed to quantify the incidence of DKA according age and describe time trend among adults diabetes Denmark. RESEARCH DESIGN AND METHODS Individuals aged ≥18 years were identified from nationwide Danish register. Hospital admissions due ascertained National Patient Register. The follow-up period was 1996 2020. RESULTS cohort consisted 24,718 rate per 100 person-years...
Rationale The hormone glucagon-like peptide-1 (GLP-1) decreases blood glucose and appetite. Greater physical activity (PA) is associated with lower incidence of type 2 diabetes. While acute exercise may increase glucose-induced response GLP-1, it unknown how habitual PA affects GLP-1 secretion. We hypothesised that associates greater responses in overweight individuals. Methods Cross-sectional analysis levels concentrations 1326 individuals (mean ( s.d. ) age 66 (7) years, BMI 27.1 (4.5)...
The oral glucose tolerance test (OGTT) is together with haemoglobin A
To assess the effects of dapagliflozin, metformin and exercise treatment on changes in plasma glucagon concentrations individuals with overweight HbA1c-defined prediabetes.One-hundred twenty (body mass index ≥ 25 kg/m2 ) prediabetes (HbA1c 39-47 mmol/mol) were randomized to a 13-week intervention dapagliflozin (10 mg once daily), (850 twice (30 minutes interval training 5 days per week) or control (habitual living). A 75-g oral glucose tolerance test (OGTT) (0, 30, 60 120 minutes) was...
Abstract Background Individuals diagnosed with and treated for type 1 diabetes (T1D) have increased risk of micro- macrovascular disease excess mortality. Improving cardiovascular (CV) factors in individuals T1D is known to reduce diabetes- related CV complications. Aim To examine time trends factor levels CV-protective treatment patterns. Additionally, incidence rates diabetes-related complications relation exposure treatment. Methods We analysed records from 41,630 T1D, registered anytime...
Physical activity (PA) is important in the prevention of Type 2 diabetes, yet little known about role specific dimensions PA, including sedentary time subgroups at risk for impaired glucose metabolism (IGM). We applied a data-driven decision tool to identify PA associated with IGM across age, sex, and body mass index (BMI) groups.This cross-sectional study included 1501 individuals (mean (SD) 65.6 (6.8) yr) high diabetes from ADDITION-PRO study. was measured by an individually calibrated...
To explore how participating in a randomised controlled trial affected motivation, barriers and strategies the process of health behaviour change among individuals with prediabetes.An extension to PRE-D trial, qualitative study investigated efficacy glucose-lowering interventions (metformin, dapagliflozin or exercise) compared control group prediabetes overweight/obesity. Data were collected through separate focus interviews participants using semi-structured interview guides inspired by...
To assess lipid-lowering drug (LLD) use patterns during 1996-2017 and examine lipid levels in relation to the of LLDs prevalent atherosclerotic cardiovascular disease (ASCVD).Using a nationwide diabetes register, 404 389 individuals with type 2 living Denmark were identified. Individuals followed from 1 January 1996 or date diagnosis until emigration, death 2017. Redemptions prescribed ascertained Register Medicinal Products Statistics. Data on sourced National Laboratory Database since...